Michael Jon Barlin Pediatric Research Program

Approximately 15‐20 percent of people with lupus are diagnosed prior to reaching the age of 18. Tens of thousands of children and adolescents in the United States today are dealing with lupus.

Our Approach and Focus on Pediatric Lupus Research

In 2006, we established the Michael Jon Barlin Pediatric Research Program with the generous support of the Wallace H. Coulter Foundation, in memory of Michael Jon Barlin, who passed away at the age of 24 following a long battle with lupus. With those funds, we became the first and only lupus organization in the United States with a dedicated childhood lupus research agenda. Through this program, we provide funding to facilitate childhood lupus research in areas where there is the greatest need, including lupus nephritis and neuropsychiatric lupus.

Below is a brief summary of several critical areas of pediatric lupus research that your donations to the Lupus Foundation of America help to support.

Lupus Nephritis in Children

Lupus in children tends to be more severe than in adults and often involves multiple organ systems, including the kidneys. Lupus‐related kidney inflammation, one of the most prominent and serious complications of lupus, is known as lupus nephritis. Up to 80 percent of children with lupus will develop lupus nephritis which, if not adequately controlled, can lead to kidney failure, the need for chronic dialysis or kidney transplantation, and potentially death.

Unfortunately, too few studies to date have investigated children with lupus nephritis in efforts to determine the best regimen of drugs to treat it. Currently, treatment approaches for lupus nephritis in children are not standardized and can vary widely across physicians. Thus, there is an urgent need to tailor lupus nephritis drug treatments specifically for children with lupus, rather than using guidelines established for adults.

The LFA is leading efforts in this critical area by providing funding to facilitate research on children with lupus, including

  • Development of drug treatments tailored specifically for children with lupus nephritis
  • Assessment of side effects of drugs being used to treat lupus nephritis in children
  • Development of new blood tests to improve the tracking of lupus nephritis in children

Neuropsychiatric Lupus in Children

Neurological or psychiatric conditions that develop in people with lupus are referred to as neuropsychiatric lupus (NPSLE). NPSLE is arguably the least understood manifestation of lupus and occurs more frequently, earlier in the course of the disease, and with greater severity in children than in adults with lupus.

Approximately 25 percent of children and adolescents with lupus develop neuropsychiatric complications, such as strokes, seizures, difficulties in thinking, and even brain damage. NPSLE is difficult to diagnose and can be present even when disease activity in other organs cannot be identified. As well, NPSLE and its treatments can negatively impact cognitive ability, school performance, and impair educational progress overall.

The LFA is the only lupus advocacy group with a robust research effort focused on NSPLE in children, and is supporting advances in this area on critical topics, such as:

  • Identification of risk factors and biomarkers
  • Use of advanced methods to identify reduced blood flow and possible brain damage in children with lupus early in the disease course
  • Development of standardized methods to assess the impact of NPSLE over time

Health‐Related Quality of Life in Pediatric Lupus

While the effects of lupus on different aspects of health and well‐being have been extensively studied in adults with lupus, their impact on children with lupus has not received the same attention. Children and adolescents with lupus often face unique and complex social and emotional issues (often related to the side effects of drugs used to treat lupus) which can greatly impact their self‐perception and overall quality of life. Their perception of their overall health can provide valuable insights about the many ways that lupus affects their life.

The transition from adolescence to early adulthood is a fragile period for young people with lupus, characterized by changes in biological and social development that can greatly influence how—or if—they will manage their disease. Especially when adolescents move away from home and are charged with caring for themselves, they can experience lupus flares (periods of increased disease activity), which, unattended, can lead to organ failure and even death. Thus, it is essential that they fully understand lupus and how to adequately manage their disease.

To this end, we recognize the great importance of properly transitioning from pediatric to adult lupus care, and is leading the way to provide significant funding to facilitate research inthis area, including:

  • Evaluation of social and psychological effects of lupus and its drug treatments on children with lupus
  • Investigations of disease and drug treatment effects on social acceptance, education and school attendance, and medication adherence
  • Development, implementation, and validation of tools to measure quality of life in children with lupus
  • Development of strategies to educate adolescents with lupus about appropriate selfcare

Accelerating Understanding of Pediatric Lupus

Our Foundation takes a strategic approach to investigating lupus in children by calling on some of the greatest minds in the field to address the most critical issues that have stood in the way of progress, and hold the greatest promise for accelerating our understanding of how lupus affects children and adolescents. Yet, despite the significant need to better understand childhood lupus and find new, safe, and effective strategies to help manage the disease, research funding to investigate lupus in children is extremely scarce. While significant progress has been made, there is still so much work to be done. Your generous contribution will allow us to continue searching for the next breakthrough that will improve care for all children and adolescents with the complex and life‐altering disease called lupus.